News Glaukos Corporation

Equities

GKOS

US3773221029

Real-time Estimate Cboe BZX Other stock markets 01:52:41 2024-04-19 pm EDT			5-day change	1st Jan Change
96.42 ^USD	+1.36%		-2.06%	+21.03%

Apr. 11	Mizuho Securities Adjusts Price Target on Glaukos to $100 From $85, Maintains Neutral Rating	MT
Apr. 11	Glaukos Insider Sold Shares Worth $6,008,359, According to a Recent SEC Filing	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Glaukos Announces the Release of its 2023 Sustainability Report	Apr. 16	BU
Mizuho Securities Adjusts Price Target on Glaukos to $100 From $85, Maintains Neutral Rating	Apr. 11	MT
Glaukos Insider Sold Shares Worth $6,008,359, According to a Recent SEC Filing	Apr. 11	MT
Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1	Apr. 10	BU
Sector Update: Health Care Stocks Rise Wednesday Afternoon	Apr. 03	MT
Glaukos Says iDose TR Assigned Permanent J-Code From US Centers for Medicare and Medicaid Services	Apr. 03	MT
Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)	Apr. 03	BU
Glaukos Corporation Receives Permanent J-Code for iDose TR (travoprost intracameral implant)	Apr. 03	CI
Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting	Apr. 01	BU
Translational Vision Science and Technology Journal Publishes RadiusXR's NOVA Clinical Trial, Demonstrating Industry-Leading Accuracy and Innovation in Visual Field Testing for Virtual Reality Perimetry	Mar. 26	AQ
Glaukos Insider Sold Shares Worth $1,153,557, According to a Recent SEC Filing	Mar. 08	MT
Celanese Announces Commercial Launch of Glaukos' iDose TR (Travoprost Intracameral Implant) using Celanese's VitalDose Ethylene Vinyl Acetate (EVA)	Mar. 01	AQ
Glaukos Insider Sold Shares Worth $736,000, According to a Recent SEC Filing	Feb. 29	MT
Glaukos Insider Sold Shares Worth $423,487, According to a Recent SEC Filing	Feb. 27	MT
Wells Fargo Hikes Price Target on Glaukos to $103 From $83, Maintains Overweight Rating	Feb. 22	MT
Needham Raises Price Target on Glaukos to $108 From $105, Maintains Buy Rating	Feb. 22	MT
Glaukos : Q4 2023 Earnings Transcript	Feb. 21	PU
Glaukos Q4 Non-GAAP Loss Widens, Sales Increase	Feb. 21	MT
Earnings Flash (GKOS) GLAUKOS CORPORATION Reports Q4 Revenue $82.4M, vs. Street Est of $78.5M	Feb. 21	MT
Transcript : Glaukos Corporation, Q4 2023 Earnings Call, Feb 21, 2024	Feb. 21

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Glaukos Corporation

Equities

GKOS

US3773221029

Summary

Filters